Yin Li meets with leaders of multinational pharmaceutical companies and associations.

Yesterday morning, Beijing Municipal Party Secretary Yin Li met with leaders of multinational pharmaceutical companies and associations. Yin Li said that in recent years, the Chinese government has attached great importance to people's health and has placed the safeguarding of people's health in a strategic position of priority development. China has explored a path of reform and development of the health care industry that is in line with China's national conditions, and has built the world's largest medical security system, significantly improving the overall health level of the population. The average life expectancy of Beijing residents is close to 84 years, and the infant mortality rate is 1.3. Beijing is not only the political center, cultural center, international exchange center, and technological innovation center of China but also a highland for the innovative development of the biopharmaceutical industry. The pharmaceutical market in Beijing is large, with strong research capabilities. In recent years, Beijing has continuously optimized the support policies throughout the entire chain to promote the rapid development of the pharmaceutical and health industry, with an industry scale exceeding one trillion yuan. Multinational pharmaceutical companies and industry associations have long been deeply rooted in China and Beijing, making positive contributions to the health cause of China and the construction of a healthy Beijing. It is hoped that everyone will deepen the collaborative innovation in medicine with Beijing, promote the transformation and application of scientific and technological innovation outcomes, expand the application of artificial intelligence in drug discovery, clinical trials, intelligent diagnosis, and other scenarios, and enhance the level of integration and innovation of "artificial intelligence + medicine". Further increase investment and layout in Beijing, actively participate in the construction of international medical innovation parks, jointly promote the development of the pharmaceutical industry, launch more innovative products and services that are tailored to the market and the health needs of residents, and benefit more patients. Together, strengthen international health exchange and cooperation, and contribute more to promoting the construction of a global community of health and well-being.